Advertisement
UK markets closed
  • NIKKEI 225

    38,460.08
    +907.92 (+2.42%)
     
  • HANG SENG

    17,201.27
    +372.34 (+2.21%)
     
  • CRUDE OIL

    82.64
    -0.72 (-0.86%)
     
  • GOLD FUTURES

    2,338.10
    -4.00 (-0.17%)
     
  • DOW

    38,383.35
    -120.34 (-0.31%)
     
  • Bitcoin GBP

    52,006.18
    -1,610.10 (-3.00%)
     
  • CMC Crypto 200

    1,398.30
    -25.80 (-1.81%)
     
  • NASDAQ Composite

    15,679.09
    -17.55 (-0.11%)
     
  • UK FTSE All Share

    4,374.06
    -4.69 (-0.11%)
     

Is Vaxart a Buy?

Is Vaxart a Buy?

In the early days of the pandemic, Vaxart (NASDAQ: VXRT) mesmerized investors after beginning development of a tablet-based, room-temperature-stable coronavirus vaccine. On Feb. 3, Vaxart announced that its oral coronavirus-vaccine candidate, VXA-CoV2-1, did not induce neutralizing antibodies after a one-dose regimen. The discrepancy here puzzled many investors since the two should be in tandem with one another, as with of the coronavirus vaccines currently on the market.